Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker INBX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 3,000 | $101.70 | $305.1K Buy | Form 4 ↗ |
| Sep 28, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 1,500 | $98.88 | $148.3K Buy | Form 4 ↗ |
| Sep 25, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 2,176 | $99.60 | $216.7K Buy | Form 4 ↗ |
| Sep 25, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 3,324 | $98.87 | $328.6K Buy | Form 4 ↗ |
| Sep 23, 2026 | Jon Faiz Kayyem Director | INBX Inhibrx Biosciences, Inc. | Buy | 5,000 | $100.00 | $500.0K Buy | Form 4 ↗ |
| Sep 16, 2026 | Jon Faiz Kayyem Director | INBX Inhibrx Biosciences, Inc. | Buy | 5,000 | $100.00 | $500.0K Buy | Form 4 ↗ |
| Sep 15, 2026 | Kimberly Manhard Director | INBX Inhibrx Biosciences, Inc. | Sale | 500 | $105.05 | $52.5K Sale | Form 4 ↗ |
| Sep 14, 2026 | Kimberly Manhard Director | INBX Inhibrx Biosciences, Inc. | Sale | 500 | $110.26 | $55.1K Sale | Form 4 ↗ |
| Sep 11, 2026 | Kimberly Manhard Director | INBX Inhibrx Biosciences, Inc. | Sale | 500 | $111.78 | $55.9K Sale | Form 4 ↗ |
| Sep 9, 2026 | Kimberly Manhard Director | INBX Inhibrx Biosciences, Inc. | Sale | 500 | $115.80 | $57.9K Sale | Form 4 ↗ |
| Sep 8, 2026 | Jon Faiz Kayyem Director | INBX Inhibrx Biosciences, Inc. | Buy | 5,000 | $113.52 | $567.6K Buy | Form 4 ↗ |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 9,681 | $112.28 | $1.1M Buy | Form 4 ↗ |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 1,219 | $111.88 | $136.4K Buy | Form 4 ↗ |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 500 | $108.24 | $54.1K Buy | Form 4 ↗ |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 1,100 | $107.12 | $117.8K Buy | Form 4 ↗ |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 6,605 | $100.64 | $664.7K Buy | Form 4 ↗ |
| Sep 8, 2026 | Mark Lappe Chief Executive Officer, Director | INBX Inhibrx Biosciences, Inc. | Buy | 5,895 | $99.29 | $585.3K Buy | Form 4 ↗ |
| Sep 8, 2026 | Douglas Forsyth Director | INBX Inhibrx Biosciences, Inc. | Buy | 2,500 | $114.65 | $286.6K Buy | Form 4 ↗ |
| Sep 8, 2026 | Kimberly Manhard Director | INBX Inhibrx Biosciences, Inc. | Sale | 500 | $115.14 | $57.6K Sale | Form 4 ↗ |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC 10% owner | INBX Inhibrx Biosciences, Inc. | Sale | 25,042 | $32.25 | $807.6K Sale | Form 4 ↗ |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC 10% owner | INBX Inhibrx Biosciences, Inc. | Sale | 16,315 | $32.25 | $526.2K Sale | Form 4 ↗ |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC 10% owner | INBX Inhibrx Biosciences, Inc. | Sale | 308,643 | $32.25 | $10.0M Sale | Form 4 ↗ |
| Nov 20, 2024 | Jon Faiz Kayyem Director | INBX Inhibrx Biosciences, Inc. | Buy | 18,750 | $14.19 | $266.1K Buy | Form 4 ↗ |
| Nov 20, 2024 | Jon Faiz Kayyem Director | INBX Inhibrx Biosciences, Inc. | Buy | 18,750 | $14.19 | $266.1K Buy | Form 4 ↗ |
| Nov 19, 2024 | Jon Faiz Kayyem Director | INBX Inhibrx Biosciences, Inc. | Buy | 34,843 | $14.23 | $495.8K Buy | Form 4 ↗ |
| Nov 19, 2024 | Jon Faiz Kayyem Director | INBX Inhibrx Biosciences, Inc. | Buy | 34,843 | $14.23 | $495.8K Buy | Form 4 ↗ |
| Oct 3, 2024 | Kristiina Vuori MD Director | INBX Inhibrx Biosciences, Inc. | Buy | 6,667 | $15.00 | $100.0K Buy | Form 4 ↗ |
27 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances